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Background: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by 
vascular changes and progressive fibrosis of skin and various internal organs. A variety of 
circulating autoantibodies have been detected in SSc. Some of them are well-established tools 
strongly associated with SSc and useful for diagnosis and management of the disease (e.g. 
ANA, anti-centromere, anti-topoisomerase I, anti-RNA polymerase III – RNAP III). Other 
autoantibodies are less frequent and non-specific for SSc even if potentially useful to better 
assess clinical subsets and prognosis (e.g. anti-Th/To, anti-Ku, anti-PM/Scl). 
Objectives: To investigate the prevalence of anti-Th/To, anti-Ku, anti-RNAP III and anti-PM/Scl 
antibodies as well as to study the associations between these antibodies and clinical features in 
Italian SSc patients. 
Methods: Sera from 176 consecutive patients with SSc collected at two Italian sites were 
tested for anti-Th/To (anti-Rpp25 and anti-Rpp38), anti-Ku, anti-RNAP III, anti-PM/Scl, and 
anti-centromere antibodies (anti-CENP-A and B) using QUANTA Flash chemiluminescence 
immunoassays (CIAs) on the BIO-FLASH instrument (Inova Diagnostics, San Diego, USA). 
Additionally, ANA screening was performed using QUANTA Flash CTD Screen Plus which includes 
the most relevant nuclear/cytoplasmic antigens. The Italian cohort included: women 162 (92%), 
limited cutaneous (lc-SSc) subtype 137 (78%), patients with present or past history of digital 
ulcers 56 (32%), calcinosis 25 (14%), lung fibrosis 69 (39%), heart involvement 22 (12.5%), 
pulmonary arterial hypertension 11 (6%) and esophageal involvement 84 (48%). 
Results: 152 (86.4%) patients were CTD Screen Plus positive, 8 (4.5%) anti-Th/To positive, 8 
(4.5%) anti-Ku positive, 20 (11.4%) anti-RNAP III positive, 0 (0%) anti-PM/Scl positive, 70 
(39.8%) anti-CENP-A positive, and 87 (49.3%) anti-CENP-B positive. Anti-CENP-A, anti-CENP-B 
and anti-Ku antibodies were significantly associated with the lc-SSc subtype 
(p<0.0001, p<0.0001 and p=0.0469, respectively). None of patients positive for anti-Ku 
antibodies displayed digital ulcers (p=0.0075). Anti-Th/To (Rpp25) antibodies were associated 
with the presence of calcinosis (p=0.0399) while anti-RNAP III antibodies with its absence 
(p=0.0353). All patients positive for anti-Th/To were positive for the Rpp25 component while 
only one of them was also positive for the Rpp38 component. 
Conclusions: The present study points out the low prevalence of anti-RNAP III and highlights a 
lower prevalence of anti-Th/To in Italian SSc patients. Several known associations between 
autoantibodies as SSc subsets have been confirmed while others could not be verified in the 
study. This supports the potential utiliy of autoantibodies to stratify SSc into clinical subsets. 
Large international multi-center studies are required to define and validate rare autoantibodies 
such as anti-Th/To, anti-Ku and anti-PM/Scl antibodies. 
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